NCT01535430: Assessment of Eloquent Function in Brain Tumor Patients

NCT01535430
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting

Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 19 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have brain metastasis in an area of eloquent brain function (speech, motor, sensory)
Exclusions: 
https://ClinicalTrials.gov/show/NCT01535430

Comments are closed.

Up ↑